KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Share-based Compensation (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Share-based Compensation for 13 consecutive years, with $14.1 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 3.79% to $14.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $53.7 million through Dec 2025, up 5.9% year-over-year, with the annual reading at $53.7 million for FY2025, 5.9% up from the prior year.
  • Share-based Compensation for Q4 2025 was $14.1 million at Xenon Pharmaceuticals, up from $13.7 million in the prior quarter.
  • The five-year high for Share-based Compensation was $14.7 million in Q2 2024, with the low at $2.0 million in Q1 2021.
  • Average Share-based Compensation over 5 years is $8.4 million, with a median of $8.6 million recorded in 2023.
  • The sharpest move saw Share-based Compensation skyrocketed 117.25% in 2022, then decreased 6.82% in 2025.
  • Over 5 years, Share-based Compensation stood at $2.7 million in 2021, then soared by 114.86% to $5.8 million in 2022, then surged by 57.98% to $9.2 million in 2023, then surged by 48.1% to $13.6 million in 2024, then grew by 3.79% to $14.1 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $14.1 million, $13.7 million, and $13.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.